Company profile
CURIS INC
NASDAQ:CRISBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| FIMEPINOSTAT | phase2 | — | 3 | no active trials |
| CENOPODLIN | phase1 | — | 1 | no active trials |
| CUDC-101 | phase1 | — | 4 | completed, terminated |
| GDC-0917 | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00728793 | phase1 | completed | 2008-08-01 | 2010-04-01 | Curis, Inc. | A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors |
| NCT01171924 | phase1 | completed | 2010-07-01 | 2011-10-01 | Curis, Inc. | A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors |
| NCT02812875 | phase1 | completed | 2016-05-01 | 2020-05-07 | Curis, Inc. | A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas |
| NCT07271667 | phase2 | recruiting | 2026-04-23 | 2027-11-01 | Curis, Inc. | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies |
| NCT03328078 | phase1_2 | recruiting | 2017-12-28 | 2027-07-01 | Curis, Inc. | CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) |
FDA applications (0)
No records yet.